<DOC>
	<DOCNO>NCT01854424</DOCNO>
	<brief_summary>Fibrocyte monocyte sub-population involve fibroproliferation/repair process associate outcome different disease . In previous study , demonstrate presence alveolar fibrocytes Acute expiratory Distress Syndrome ( ARDS ) association patient outcome . The purpose multicentric observational prospective study describe percentage alveolar fibrocytes ICU patient ARDS ( survivor vs. non survivor ) confirm association 28-day mortality .</brief_summary>
	<brief_title>Validation Percentage Alveolar Fibrocyte Biomarker During ARDS</brief_title>
	<detailed_description>Background : The acute respiratory distress syndrome ( ARDS ) remain common ( 15 % ventilated patient ICU ) , severe ( 30 % mortality ) specific treatment . Impaired epithelial repair fibroproliferation observe non resolutive form ARDS . Fibrocytes cell express marker hematopoietic cell ( CD34+ , CD45+ ) fibroblast ( collagen-1 ) . Fibrocytes may recruit directly pool circulate blood monocyte also derive monocyte situ absence serum amyloid P ( SAP pentraxin-2 ) . In murine model lung injury , show fibrocytes recruit lung contribute local fibrogenesis . Our team first demonstrate ARDS human presence fibrocytes among alveolar cell obtain bronchoalveolar lavage ( BAL ) ( Quesnel et al , Eur Resp J , 2010 ) . In second single-center work enrol 122 patient , show percentage alveolar fibrocytes &gt; 6 % associate increased risk death ( HR = 6.2 [ 2.8 13.6 ] , p &lt; 0.0001 ) . However , result remain confirmed second cohort main objective first study variable lead time BAL sample cohort patient ARDS ( Quesnel et al , CCM , 2012 ) . Furthermore , correlation percentage blood fibrocytes ( Fsg % ) percentage alveolar fibrocytes ( Fal % ) remain unknown kinetics remain studied ARDS evolution . Hypothesis Objective : We hypothesize percentage alveolar fibrocytes prognostic marker ARDS . Our main goal confirm validation cohort % alveolar fibrocytes measure BAL fluid first 48 hour ARDS evolution associate 28-day mortality .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Respiratory Distress Syndrome , Newborn</mesh_term>
	<mesh_term>Respiratory Distress Syndrome , Adult</mesh_term>
	<mesh_term>Acute Lung Injury</mesh_term>
	<criteria>Ventilated patient ARDS criterion define Berlin criterion first 48 hour evolution . refusal patient participation , pregnancy , HIV infection , Respiratory insufficiency , Pulmonary fibrosis , cirrhosis ( &gt; Child B score ) , scleroderma , Alzheimer 's disease , Bone marrow transplant , chemotherapyinduced aplasia , immunosuppressive therapy , Corticosteroids ( &gt; 200 mg/day hydrocortisone equivalent two week precede inclusion ) , End life patient IGS2 great 90 , brain death , therapeutic limitation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Fibrocyte</keyword>
	<keyword>Acute Respiratory Distress Syndrome</keyword>
	<keyword>Serum Amyloid P</keyword>
	<keyword>Fibrosis</keyword>
	<keyword>Mortality</keyword>
</DOC>